cetuximab
cetuximab
Overview
Cetuximab (brand name Erbitux) is a recombinant chimeric IgG1 monoclonal antibody that targets the extracellular domain of the epidermal growth factor receptor (EGFR), a transmembrane receptor tyrosine kinase that is overexpressed or dysregulated in numerous solid tumors. By competitively blocking ligand binding to EGFR, cetuximab inhibits downstream pro-proliferative signaling cascades—including the RAS/MAPK and PI3K/AKT pathways—thereby suppressing tumor cell growth, angiogenesis, invasion, and metastasis. In addition to its direct antagonistic mechanism, cetuximab's IgG1 Fc region confers potent immune effector functions, most notably antibody-dependent cellular cytotoxicity (ADCC) mediated by natural killer (NK) cells, which contributes meaningfully to its antitumor activity in EGFR-expressing tumors. Originally approved for the treatment of KRAS wild-type metastatic colorectal cancer and squamous cell carcinoma of the head and neck, cetuximab is frequently administered in combination with chemotherapy backbones such as FOLFOX or irinotecan hydrochloride-containing regimens.
Cetuximab occupies a central position in the oncology landscape as a benchmark anti-EGFR antibody against which emerging therapies are compared. Its clinical utility is closely tied to tumor molecular profiling, particularly KRAS and BRAF mutation status, which guide patient selection. Despite robust initial responses in biomarker-selected populations, intrinsic and acquired resistance to cetuximab remains a significant clinical challenge, motivating active research into resistance mechanisms, combinatorial strategies, and next-generation EGFR-targeting modalities. Structurally, cetuximab serves as a well-characterized reference antibody in analytical chemistry and biopharmaceutical development, alongside other therapeutic monoclonal antibodies such as trastuzumab and bevacizumab.
Focus of Latest Publications
Recent publications on cetuximab have focused on its use in combination regimens, imaging platforms, resistance biology, and practical treatment-related assessment. In locally advanced head and neck squamous cell carcinoma, cetuximab was evaluated as part of neoadjuvant paclitaxel, carboplatin, and cetuximab (PCE) “bridging therapy” intended to control tumor progression during the preoperative waiting period and support safe transition to surgery. In head and neck photoimmunotherapy, cetuximab sarotalocan sodium was used in a study assessing a simplified artificial irradiator for post-treatment photosensitivity testing, with the goal of providing more standardized and weather-independent light exposure than direct sunlight.
Several recent studies examined cetuximab in colorectal cancer. A cost-effectiveness analysis in BRAF V600E-mutant metastatic colorectal cancer assessed encorafenib plus cetuximab, with or without mFOLFOX6, versus standard of care using data from the BREAKWATER trial; both cetuximab-containing strategies exceeded the willingness-to-pay threshold in China, indicating they were not cost-effective at current prices. Another retrospective analysis of chemoport-related right innominate vein stenosis in patients with colorectal cancer included a subgroup evaluation of palliative chemotherapy and found that bevacizumab, but not cetuximab, was associated with increased stenosis risk. In left-sided metastatic colorectal cancer, a multicenter real-world observational study compared first-line cetuximab- and panitumumab-based doublet chemotherapy, reflecting ongoing interest in how cetuximab performs relative to other anti-EGFR antibodies in routine practice.
Other publications extended cetuximab into diagnostic and translational research. A preclinical head and neck squamous cell carcinoma study developed [111In]In-WAZABY, a bimodal SPECT/NIR fluorescence probe created by conjugating a water-soluble aza-BODIPY fluorophore to cetuximab; the probe specifically accumulated in EGFR-expressing tumors and showed strong concordance between optical and SPECT signals, supporting its potential for peroperative tumor localization and fluorescence-guided surgery. In a separate mechanistic study on overcoming acquired EGFR resistance, investigators developed novel EGFR antibodies and bispecific EGFR×CD3 T-cell engagers that bound epitopes overlapping but distinct from the cetuximab-binding site and retained activity against EGFR extracellular domain escape variants such as S492R and G465R, highlighting cetuximab resistance as a key driver of next-generation therapeutic design. Cetuximab also appeared in an analytical context, where LC-MS peptide mapping showed that Tryp-N provided sequence coverage for cetuximab comparable to trypsin and could improve characterization of post-translational modifications and sequence variants.
Key Publications
- NEWJan Utility of a Simplified Irradiator for Photosensitivity Testing in Head and Neck Photoimmunotherapy. (In vivo (Athens, Greece), 2026, PMID 42379786): "Head and neck photoimmunotherapy (HN-PIT) using cetuximab sarotalocan sodium requires post-treatment assessment for photosensitivity, but tests using direct sunlight are affected by weather and lack standardization."
- NEWJul Neoadjuvant Chemotherapy With Paclitaxel, Carboplatin, and Cetuximab for Locally Advanced Head and Neck Cancer. (Anticancer research, 2026, PMID 42373242): "This study evaluated the clinical and pathological responses to neoadjuvant paclitaxel, carboplatin, and cetuximab (PCE) therapy used as a "bridging therapy" to ensure safe transition to surgery."
- May Cost-effectiveness analysis of encorafenib in untreated BRAF V600E-mutant metastatic colorectal cancer in China. (The pharmacogenomics journal, 2026, PMID 42185244): "This study assessed the cost-effectiveness of encorafenib plus cetuximab (EC) and EC combined with mFOLFOX6 versus standard of care (SOC) as first-line treatment for BRAF V600E-mutant metastatic colorectal cancer from a Chinese healthcare perspective."
- May Chemoport-related right innominate vein stenosis in patients with colorectal cancer: A retrospective risk factor analysis. (PloS one, 2026, PMID 42160312): "In the 728 palliative patients, bevacizumab treatment was significantly associated with a higher risk of CR-RIVS (hazard ratio=1.51, 95% confidence interval: 1.25-1.82, P<0.001), whereas cetuximab was not (p=0.85)."
- May Novel bispecific T-cell engagers overcoming acquired EGFR resistance. (mAbs, 2026, PMID 42152476): "However, intrinsic and acquired resistance to EGFR-targeted antibody therapies such as cetuximab remains a major limitation to achieving broad and durable treatment responses."
- May SPECT/NIR Fluorescence Bimodal Use of Aza-BODIPY Probe Coupled with Cetuximab for Detection of Cancer: Proof of Concept on a Preclinical Head and Neck Squamous Cell Carcinoma Model. (Journal of medicinal chemistry, 2026, PMID 42012405): "The platform enables the design of a bimodal imaging probe through conjugation to the anti-epithelial growth factor receptor (EGFR) antibody cetuximab and incorporation of a [111In]In-DOTA complex for single-photon emission computed tomography (SPECT) imaging."
- May Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum. (International journal of clinical oncology, 2026, PMID 41779341): "the recommended first-line treatment is anti-epidermal growth factor receptor (anti-EGFR) antibodies, such as cetuximab or panitumumab, plus doublet chemotherapy."
- May LC-MS peptide mapping of monoclonal antibodies using the mirror proteases trypsin and Tryp-N. (Journal of pharmaceutical and biomedical analysis, 2026, PMID 41570394): "The sequence coverages achieved for bevacizumab, cetuximab, NISTmAb, and trastuzumab with Tryp-N were comparable to that of trypsin."